3-(4-chlorophenyl)-9-methoxy-1-phenyl-5H-chromeno[3,4-b]pyridin-5-one | 1414381-95-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3-(4-chlorophenyl)-9-methoxy-1-phenyl-5H-chromeno[3,4-b]pyridin-5-one
• 英文别名: 3-(4-Chlorophenyl)-9-methoxy-1-phenylchromeno[3,4-b]pyridin-5-one；3-(4-chlorophenyl)-9-methoxy-1-phenylchromeno[3,4-b]pyridin-5-one
• CAS: 1414381-95-5
• 化学式: C₂₅H₁₆ClNO₃
• 分子量: 413.86
• InChiKey: BRDBXKLMOQWTJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-氯苯甲醛 、 6-methoxy-3-aminocoumarin 、 苯乙炔 在 碘 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以78%的产率得到3-(4-chlorophenyl)-9-methoxy-1-phenyl-5H-chromeno[3,4-b]pyridin-5-one
  参考文献：
  名称：

  A simple and expedient synthesis of functionalized pyrido[2,3-c] coumarin derivatives using molecular iodine catalyzed three-component reaction

  摘要：

  A wide variety of substituted pyrido[2,3-c] coumarin derivatives have been accomplished from 3-aminocoumarins, aromatic aldehydes, and alkynes in the presence of 10 mol % molecular iodine in acetonitrile under reflux conditions through one-pot Povarov reactions. Good yields, no need of aqueous work-up procedure and chromatographic separation, environmentally benign are some of the salient features of the present protocol. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2012.09.051

文献信息

• A simple and expedient synthesis of functionalized pyrido[2,3-c] coumarin derivatives using molecular iodine catalyzed three-component reaction
  作者：Abu T. Khan、Deb K. Das、Kobirul Islam、Pradipta Das

  DOI：10.1016/j.tetlet.2012.09.051

  日期：2012.11

  A wide variety of substituted pyrido[2,3-c] coumarin derivatives have been accomplished from 3-aminocoumarins, aromatic aldehydes, and alkynes in the presence of 10 mol % molecular iodine in acetonitrile under reflux conditions through one-pot Povarov reactions. Good yields, no need of aqueous work-up procedure and chromatographic separation, environmentally benign are some of the salient features of the present protocol. (C) 2012 Elsevier Ltd. All rights reserved.